Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Afinitor

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

Boehringer drug approved in EU for rare lung disease

Nintedanib is already available as cancer treatment

- PMLiVE

RCGP animation to improve patient care

Encourages doctors to consider a holistic approach to care planning

- PMLiVE

Janssen will cover cost of unsuccessful hepatitis C treatment

NHS England will only have to pay for Olysio if patient clears virus

- PMLiVE

Pharma condemns Cancer Drugs Fund cuts

NHS England says 16 medicines across 25 indications will be removed from list

- PMLiVE

NICE says cost of Dendreon’s cancer vaccine is too high

Another blow as the bankrupt company goes to auction next month

Shire Basingstoke

Shire signs deal to buy NPS for $5.2bn

Firm hopes to boost its presence in rare disease sector

- PMLiVE

NHS England names director for new models of care

Samantha Jones recently won NHS chief executive of the year

- PMLiVE

NICE rejects pancreatic cancer regimen over cost concerns

Charity says draft decision to deny Abraxane/Gemzar combo is a ‘backwards step’ for the NHS pricing body

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

- PMLiVE

NICE backs three ulcerative colitis treatments

Remicade, Simponi and Humira recommended for NHS reimbursement

- PMLiVE

Private sector on rise in England’s NHS, says BMJ

One-third of NHS contracts have gone to private providers since healthcare reforms

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links